Project Details
Description
Our ultimate goals are to understand, predict, prevent, and treat anthracycline-induced cardiotoxicity (AIC) in cancer patients receiving Anthracyclines (AC). Within the 5-year plan of this Transatlantic Network of Excellence, we intend to (see Figure):
Specific Aim 1. Elucidate the matrix of molecular signals that define the pathophysiology of AIC using in vitro and in vivo mouse models of AIC, hiPSC-CM, human myocardial slices.
Specific Aim 2. Identify and validate novel genetic/molecular signaling signatures to develop innovative biomarker strategies to identify patients at high-risk of experiencing AIC, using single cell transcriptome (SC-RNA-Seq) of human biopsy samples, blood samples and hiPSC-CM.
Specific Aim 3. Define druggable pathways and provide proof of concept pharmacological strategies for the prevention and treatment of AIC.
Specific Aim 1. Elucidate the matrix of molecular signals that define the pathophysiology of AIC using in vitro and in vivo mouse models of AIC, hiPSC-CM, human myocardial slices.
Specific Aim 2. Identify and validate novel genetic/molecular signaling signatures to develop innovative biomarker strategies to identify patients at high-risk of experiencing AIC, using single cell transcriptome (SC-RNA-Seq) of human biopsy samples, blood samples and hiPSC-CM.
Specific Aim 3. Define druggable pathways and provide proof of concept pharmacological strategies for the prevention and treatment of AIC.
| Status | Active |
|---|---|
| Effective start/end date | 1/1/20 → 12/31/24 |
Funding
- Leducq Foundation (19CVD02)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.